Clear All
11765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68382-0245-78 68382-0245 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 21, 2021 In Use
51991-0376-17 51991-0376 IMATINIB MESYLATE IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb 8, 2019 Mar 31, 2023 No Longer Used
63459-0177-14 63459-0177 Omacetaxine Mepesuccinate Synribo 3.5 mg/mL Chemotherapy Plant Alkaloid BCR-ABL Subcutaneous Nov 19, 2012 Apr 30, 2024 No Longer Used
00069-0193-01 00069-0193 Bosutinib monohydrate, Bosutinib BOSULIF 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec 18, 2017 In Use
59651-0544-60 59651-0544 DASATINIB DASATINIB 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
66993-0236-30 66993-0236 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
51991-0376-05 51991-0376 IMATINIB MESYLATE IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb 8, 2019 Mar 31, 2023 No Longer Used
66828-0030-01 66828-0030 Imatinib Mesylate Gleevec 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 15, 2001 In Use
67184-0532-01 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 21, 2022 In Use
69097-0578-56 69097-0578 nilotinib NILCEYA 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
59651-0542-60 59651-0542 DASATINIB DASATINIB 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
62135-0658-90 62135-0658 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb 28, 2024 In Use
70771-1905-03 70771-1905 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
59651-0542-15 59651-0542 DASATINIB DASATINIB 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
60505-3629-06 60505-3629 Dasatinib Dasatinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
70771-1903-06 70771-1903 Dasatinib Dasatinib 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
60687-0882-21 60687-0882 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 19, 2025 In Use
68001-0622-05 68001-0622 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 5, 2025 In Use
68382-0245-16 68382-0245 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan 21, 2021 In Use
69097-0577-56 69097-0577 nilotinib NILCEYA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
83858-0102-60 83858-0102 Dasatinib PHYRAGO 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
69097-0577-74 69097-0577 nilotinib NILCEYA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
69097-0577-73 69097-0577 nilotinib NILCEYA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
57894-0449-01 57894-0449 Teclistamab TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
61755-0056-01 61755-0056 Linvoseltamab-gcpt LYNOZYFIC 200.0 mg/10mL Immunotherapy Bispecific Antibody BCMA, CD3 Intravenous Jul 2, 2025 In Use

Found 11765 results — Export these results